|
US2004166536A1
|
|
Method for predicting whether subjects with mild cognitive impairment (MCI) will develop Alzheimer's Disease
|
|
AU5743500A
|
|
Purified antigen for alzheimer's disease, and methods of obtaining and using same
|
|
US6214994B1
|
|
Certain substituted 1-aryl-3-piperazin-1′-yl propanones
|
|
EP0862614A1
|
|
Yeast receptor and g-protein fusion protein
|
|
CA2205586A1
|
|
Certain substituted 1-aryl-3-piperazin-1'-yl propanones
|
|
CA2205530C
|
|
Use of substituted aryl-morpholino-, thiomorpholino-or piperazino-propanones for the treatment of prevention of alzheimer's disease
|
|
US5705501A
|
|
Certain substituted 1-aryl-3-morpholinopropanones to treat Alzheimer's Disease
|
|
US5658909A
|
|
Certain substituted 1-aryl-3-piperazin-1'-yl propanones to treat Alzheimer's Disease
|
|
US5693804A
|
|
Substituted 1-aryl-3-piperazin-1'-yl propanones
|
|
AU7556994A
|
|
Methods for the diagnosis of alzheimer's disease
|
